Completed PHASE4 INTERVENTIONAL 1-arm NCT01936077

Severe LH Suppressed Patients After Administration of a GnRH Antagonist (OPTOMALH)

To Define the Individual Need of Exogenous LH During Ovarian Stimulation for Severe LH Suppressed Patients After Administration of a GnRH Antagonist

Sponsor: Assuta Hospital Systems

Conditions Infertility, Female Infertility, Male Infertility

Interventions Recombinant LH (Luveris)

Updated 5 times since 2017 Last updated: Sep 2, 2013 Started: Jun 30, 2010 Primary completion: May 31, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Infertility, Female Infertility, Male Infertility and is currently completed. Assuta Hospital Systems leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assuta Hospital Systems
Maccabi Healthcare Services, Israel

Data source: Assuta Hospital Systems

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Haifa, Israel